TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 151 filers reported holding TRAVERE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,757,597 | -57.7% | 308,456 | -27.3% | 0.00% | -33.3% |
| Q2 2023 | $6,520,949 | -39.2% | 424,541 | -11.0% | 0.00% | -50.0% |
| Q1 2023 | $10,723,413 | +84.5% | 476,808 | +72.5% | 0.01% | +100.0% |
| Q4 2022 | $5,813,260 | -28.0% | 276,427 | -15.7% | 0.00% | -40.0% |
| Q3 2022 | $8,077,000 | -38.9% | 327,833 | -39.9% | 0.01% | -28.6% |
| Q2 2022 | $13,210,000 | -10.7% | 545,234 | -5.0% | 0.01% | 0.0% |
| Q1 2022 | $14,794,000 | +19.9% | 574,044 | +44.4% | 0.01% | +16.7% |
| Q4 2021 | $12,343,000 | +49.3% | 397,646 | +16.7% | 0.01% | +50.0% |
| Q3 2021 | $8,266,000 | +65.7% | 340,847 | -0.3% | 0.00% | +100.0% |
| Q2 2021 | $4,989,000 | -55.3% | 341,929 | -23.4% | 0.00% | -66.7% |
| Q1 2021 | $11,151,000 | -7.9% | 446,569 | +0.5% | 0.01% | -14.3% |
| Q4 2020 | $12,108,000 | – | 444,281 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |